FDA Awaits GAO Report To Guide Behind-The-Counter Policy
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA waits for updated report on other countries’ behind-the-counter programs before making decisions on a third class in the U.S.; report expected in late January/early February